IGF2BP3 and hepatocellular carcinoma: Recent studies have further confirmed that IGF2BP3, PCK2, NRF2, and m6A modification play significant roles in the mechanism of lenvatinib resistance in HCC, making them potential therapeutic targets for overcoming drug resistance.